Jim Simons Biotechnology

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
CORT Corcept Therapeutics Inc	$7.3B	$702 Million 1.13% of portfolio	6,143,031	Q1 2025 Reduced 0.9%
UTHR United Therapeutics Corp	$13.5B	$650 Million 1.04% of portfolio	2,106,992	Q1 2025 Added 0.84%
VRTX Vertex Pharmaceuticals Inc	$120B	$568 Million 0.91% of portfolio	1,171,571	Q1 2025 Reduced 16.15%
EXEL Exelixis, Inc.	$11.9B	$547 Million 0.88% of portfolio	14,824,265	Q1 2025 Reduced 3.08%
NVO Novo Nordisk A S	$122B	$474 Million 0.76% of portfolio	6,821,396	Q1 2025 Reduced 17.94%
INCY Incyte Corp	$17.2B	$225 Million 0.36% of portfolio	3,708,732	Q1 2025 Reduced 9.23%
JAZZ Jazz Pharmaceuticals PLC	$7.31B	$130 Million 0.21% of portfolio	1,044,574	Q1 2025 Added 4.26%
INVA Innoviva, Inc.	$1.29B	$82.6 Million 0.13% of portfolio	4,557,232	Q1 2025 Added 6.93%
CPRX Catalyst Pharmaceuticals, Inc.	$2.16B	$71.7 Million 0.12% of portfolio	2,956,316	Q1 2025 Added 9.25%
ADMA Adma Biologics, Inc.	$3.59B	$70.4 Million 0.11% of portfolio	3,548,988	Q1 2025 Reduced 5.86%
BMRN Biomarin Pharmaceutical Inc	$10.8B	$63.3 Million 0.1% of portfolio	895,771	Q1 2025 Added 105.51%
REGN Regeneron Pharmaceuticals, Inc.	$59.8B	$50 Million 0.08% of portfolio	78,901	Q1 2025 Reduced 68.15%
TVTX Travere Therapeutics, Inc.	$997M	$48.4 Million 0.08% of portfolio	2,702,814	Q1 2025 Added 12.17%
GMAB Genmab A/S	$14.9B	$44.3 Million 0.07% of portfolio	2,262,350	Q1 2025 Added 17.45%
MRNA Moderna, Inc.	$12.8B	$38.6 Million 0.06% of portfolio	1,360,100	Q1 2025 Added 34.56%
PTCT Ptc Therapeutics, Inc.	$3.53B	$34.2 Million 0.05% of portfolio	670,200	Q1 2025 Added 2.62%
MDGL Madrigal Pharmaceuticals, Inc.	$5.04B	$28.2 Million 0.05% of portfolio	85,086	Q1 2025 Reduced 47.08%
HRMY Harmony Biosciences Holdings, Inc.	$2.1B	$27.9 Million 0.04% of portfolio	840,371	Q1 2025 Added 47.78%
VCYT Veracyte, Inc.	$1.75B	$24.7 Million 0.04% of portfolio	832,000	Q1 2025 Added 38.51%
ACAD Acadia Pharmaceuticals Inc	$3.66B	$24.5 Million 0.04% of portfolio	1,477,033	Q1 2025 Added 20.42%
LEGN Legend Biotech Corp	$6.83B	$24.1 Million 0.04% of portfolio	710,900	Q1 2025 Reduced 21.72%
VNDA Vanda Pharmaceuticals Inc.	$265M	$16.4 Million 0.03% of portfolio	3,566,425	Q1 2025 Reduced 7.46%
AXSM Axsome Therapeutics, Inc.	$4.31B	$15.7 Million 0.03% of portfolio	134,400	Q1 2025 New
PTGX Protagonist Therapeutics, Inc	$2.7B	$15.6 Million 0.03% of portfolio	323,567	Q1 2025 Added 46.3%
MDXG Mimedx Group, Inc.	$758M	$14.7 Million 0.02% of portfolio	1,930,277	Q1 2025 Added 6.97%
FOLD Amicus Therapeutics, Inc.	$1.72B	$12.7 Million 0.02% of portfolio	1,561,993	Q1 2025 Reduced 25.92%
XERS Xeris Biopharma Holdings, Inc.	$691M	$11.9 Million 0.02% of portfolio	2,162,640	Q1 2025 Added 3.04%
IOVA Iovance Biotherapeutics, Inc.	$461M	$11.7 Million 0.02% of portfolio	3,511,400	Q1 2025 New
IMVT Immunovant, Inc.	$3.55B	$10.9 Million 0.02% of portfolio	395,900	Q1 2025 Added 389.37%
RARE Ultragenyx Pharmaceutical Inc.	$1.94B	$10.8 Million 0.02% of portfolio	299,600	Q1 2025 Added 17.63%
SRRK Scholar Rock Holding Corp	$1.93B	$10.2 Million 0.02% of portfolio	317,400	Q1 2025 Added 594.53%
MRVI Maravai Lifesciences Holdings, Inc.	$326M	$9.08 Million 0.01% of portfolio	4,110,689	Q1 2025 Added 3.49%
GERN Geron Corp	$431M	$8.91 Million 0.01% of portfolio	5,601,100	Q1 2025 Added 285.56%
MIRM Mirum Pharmaceuticals, Inc.	$1.88B	$8.49 Million 0.01% of portfolio	188,500	Q1 2025 Added 86.18%
TECH Bio Techne Corp	$2.27B	$8.47 Million 0.01% of portfolio	144,400	Q1 2025 New
SNDX Syndax Pharmaceuticals Inc	$585M	$8.37 Million 0.01% of portfolio	681,427	Q1 2025 Added 0.07%
GLPG Galapagos Nv	$2.16B	$8.31 Million 0.01% of portfolio	330,800	Q1 2025 Added 11.72%
MNKD Mannkind Corp	$983M	$8.3 Million 0.01% of portfolio	1,649,745	Q1 2025 Added 68.06%
SWTX Spring Works Therapeutics, Inc.	$2.93B	$8.2 Million 0.01% of portfolio	185,900	Q1 2025 New
AKRO Akero Therapeutics, Inc.	$2.2B	$8.06 Million 0.01% of portfolio	199,000	Q1 2025 Added 856.73%
VKTX Viking Therapeutics, Inc.	$2.59B	$7.91 Million 0.01% of portfolio	327,700	Q1 2025 New
AKBA Akebia Therapeutics, Inc.	$647M	$7.69 Million 0.01% of portfolio	4,005,827	Q1 2025 Added 4.77%
HALO Halozyme Therapeutics, Inc.	$8.23B	$7.66 Million 0.01% of portfolio	120,010	Q1 2025 Added 359.63%
AUPH Aurinia Pharmaceuticals Inc.	$1.27B	$7.55 Million 0.01% of portfolio	938,600	Q1 2025 Added 33.91%
PCVX Vaxcyte, Inc.	$2.06B	$7.41 Million 0.01% of portfolio	196,277	Q1 2025 Added 262.96%
VIR Vir Biotechnology, Inc.	$696M	$7.26 Million 0.01% of portfolio	1,120,400	Q1 2025 Reduced 9.47%
TGTX Tg Therapeutics, Inc.	$5.13B	$6.65 Million 0.01% of portfolio	168,594	Q1 2025 New
ARDX Ardelyx, Inc.	$654M	$6.64 Million 0.01% of portfolio	1,351,593	Q1 2025 New
ABCL Ab Cellera Biologics Inc.	$1.34B	$6.45 Million 0.01% of portfolio	2,894,029	Q1 2025 Added 16.37%
VRNA Verona Pharma PLC	$6.41B	$6.29 Million 0.01% of portfolio	99,000	Q1 2025 Added 538.71%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account